Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Survival outcomes after adjuvant radiotherapy for aggressive fibromatosis depend on time frame and nuclear β-catenin

  • Kim, Jae Sik (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Kim, Hak Jae (Department of Radiation Oncology, Seoul National University College of Medicine) ;
  • Lee, Me-Yeon (Department of Radiation Oncology, Hallym University College of Medicine) ;
  • Moon, Kyung Chul (Department of Pathology, Seoul National University College of Medicine) ;
  • Song, Seung Geun (Department of Pathology, Seoul National University College of Medicine) ;
  • Kim, Han-Soo (Department of Orthopaedic Surgery, Seoul National University College of Medicine) ;
  • Han, Ilkyu (Department of Orthopaedic Surgery, Seoul National University College of Medicine) ;
  • Kim, Il Han (Department of Radiation Oncology, Seoul National University College of Medicine)
  • Received : 2018.12.02
  • Accepted : 2019.01.18
  • Published : 2019.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To identify prognostic factors influencing progression-free survival (PFS) of aggressive fibromatosis (AF) after postoperative radiotherapy (PORT) and assess correlations between immunohistochemistry (IHC) features of β-catenin/smooth muscle actin (SMA) and PFS. Materials and Methods: Records of 37 patients with AF treated by PORT from 1984 to 2015 were retrospectively reviewed. Fifteen patients underwent wide excision for AF and 22 patients received debulking operation. The median total dose of PORT was 59.4 Gy. IHC staining results of β-catenin and SMA were available for 11 and 12 patients, respectively. Results: The median follow-up duration was 105.9 months. Five-year PFS rate was 70.9%. Tumor size or margin status was not related to PFS in univariate analysis (p = 0.197 and p = 0.716, respectively). Multivariate analysis showed that increased interval from surgery to PORT (>5.7 weeks) was a marginal risk factor for PFS (p = 0.054). Administration of PORT at the initial diagnosis resulted in significantly improved PFS compared to deferring PORT after recurrence (p = 0.045). Patient with both risk factors of deferring PORT after recurrence and interval from surgery to PORT >5.7 weeks had significantly lower 5-year PFS than patients without risk factor (34.1% vs. 100.0%; p = 0.012). Nuclear β-catenin intensity tended to inversely correlate with 5-year PFS, although it did not reach statistical significance (62.5% at low vs. 100.0% at high; p = 0.260). SMA intensity was not related to PFS (p = 0.700). Conclusion: PORT should be performed immediately after surgery irrespective of margin status or tumor size especially in recurrent case. Nuclear β-catenin staining intensity of IHC might correlate with local recurrence.

Keywords

References

  1. Harati K, Jaenisch A, Behr B, et al. Effect of surgical margins on prognosis in aggressive fibromatosis: A single-institutional analysis of 90 patients. Oncol Lett 2017;14:5129-34.
  2. Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 2017;28:2399-408. https://doi.org/10.1093/annonc/mdx323
  3. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008;173:1518-27. https://doi.org/10.2353/ajpath.2008.080475
  4. Kamath SS, Parsons JT, Marcus RB, Zlotecki RA, Scarborough MT. Radiotherapy for local control of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 1996;36:325-8.
  5. Zlotecki RA, Scarborough MT, Morris CG, et al. External beam radiotherapy for primary and adjuvant management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 2002;54:177-81.
  6. Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev 2006;20:1394-404. https://doi.org/10.1101/gad.1424006
  7. Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 2013;119:3696-702. https://doi.org/10.1002/cncr.28271
  8. Micke P, Ostman A. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 2005;9:1217-33. https://doi.org/10.1517/14728222.9.6.1217
  9. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002-11.
  10. Gebert C, Hardes J, Kersting C, et al. Expression of betacatenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology 2007;50:491-7. https://doi.org/10.1111/j.1365-2559.2007.02619.x
  11. Parikh JG, Kulkarni A, Johns C. $\alpha$-smooth muscle actin-positive fibroblasts correlate with poor survival in hepatocellular carcinoma. Oncol Lett 2014;7:573-5. https://doi.org/10.3892/ol.2013.1720
  12. Mueller C, Croner R, Klein P, Grutzmann R, Vassos N. Primary and recurrent sporadic desmoids: Prognostic factors influencing recurrence-free survival after complete gross resection. Int J Surg 2016;31:63-70. https://doi.org/10.1016/j.ijsu.2016.05.068
  13. Wirth L, Klein A, Baur-Melnyk A, et al. Desmoid tumours of the extremity and trunk: a retrospective study of 44 patients. BMC Musculoskelet Disord 2018;19:2. https://doi.org/10.1186/s12891-017-1924-3
  14. Santti K, Beule A, Tuomikoski L, et al. Radiotherapy in desmoid tumors: treatment response, local control, and analysis of local failures. Strahlenther Onkol 2017;193:269-75. https://doi.org/10.1007/s00066-016-1091-8
  15. Goy BW, Lee SP, Eilber F, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys 1997;39:659-65. https://doi.org/10.1016/S0360-3016(97)00334-9
  16. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-67. https://doi.org/10.1200/JCO.1999.17.1.158
  17. Salas S, Dufresne A, Bui B, et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011;29:3553-8. https://doi.org/10.1200/JCO.2010.33.5489
  18. Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 2007;51:509-14. https://doi.org/10.1111/j.1365-2559.2007.02794.x
  19. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol 2005;18:68-74. https://doi.org/10.1038/modpathol.3800272
  20. Orford K, Orford CC, Byers SW. Exogenous expression of betacatenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol 1999;146:855-68. https://doi.org/10.1083/jcb.146.4.855